As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
You may also be interested in...
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.
Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.